IRDye 800CW PEG Contrast Agent (25-60 kDa) is a non-specific imaging agent intended to exploit enhanced permeability and retention (EPR) in tumor biology.
EPR is a common characteristic of tumor vasculature. The vascular endothelium in the tumor microenvironment is often discontinuous, allowing molecules to diffuse into the surrounding tumor tissue.1, 2 In addition to EPR, the lymphatic drainage for these regions is poor.3 Hence, larger molecules tend to accumulate.
Learn more about LI-COR optical probes.
Applications
Absorbance and Emission Spectra
Data Examples
In appropriate mouse models, the agent highlights surface vasculature for approximately 0.5 hour post-injection as seen in Figure 1. Approximately 4 hours post-injection, retention of the labeled macromolecule is visible in the tumor (Figure 2). At 9 hours post-intravenous injection the tumor is well defined (Figure 3).
IRDye 800CW PEG Contrast Agent may also be used effectively as a lymph tracking agent when given intradermally (Figure 4). Images captured on the Pearl® Imaging System.
References
- Vasey, P.A., et al. (1999) Clin, Cancer Res, 5:83-94.
- Matsumura, Y. and H. Maeda. (1986) Cancer Res, 46:6387-6392.
- Seymour, L.W. (1992) Crit. Rev. Ther. Drug Carrier Syst, 9(2):135-187.